In a historic and surprise move, this week the US declared its support for a patent waiver on COVID-19 vaccines.
Though risk is lower, researchers debate whether people should be encouraged to wear masks outdoors or should efforts instead focus on reducing indoor transmission?
While numbers indicate that the risks of COVID-19 still outweigh potential vaccine side effects, the current pause in vaccine distribution demonstrate the system is working and the public is onboard.
Assays using pseudoviruses have been indispensable in our efforts to halt the current pandemic.
The strength of immune responses after the first dose of COVID-19 vaccines could make or break this strategy and policy makers need to be able to adapt.
First and foremost, the goal is to ultimately keep people out of hospitals. The good news is all of the currently approved vaccines do just that.
New active substances that can block the replication of the SARS-CoV-2 coronavirus discovered in proof-of-concept study.
Moisture-resistant mask filters made from compostable and abundant materials could help curb plastic pollution as a result of the pandemic.
A scientific detective story unearths how SARS-CoV-2 evolves new variants that evade antibodies.
Russia’s Sputnik V coronavirus vaccine gives around 92% protection against COVID-19, results published in The Lancet reveal.